Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Inclusion Criteria: * Male or female subjects must be greater than or equal to 18 years of age. * Subjects must have a diagnosis of Systemic Sclerosis as defined by the 2013 American College of Rheumatology criteria/EULAR criteria * Subjects must have a diagnosis or history of Raynaud's Phenomenon, self-reported or reported by a physician, with at least a 2-phase color change in finger(s) of pallor, cyanosis, and/or reactive hyperemia in response to cold exposure or emotion * Subjects must have a minimum of 10 symptomatic Raynaud's Phenomenon attacks, documented in the electronic patient-reported outcomes (ePRO) diary, occurring over at least 3 separate days of the 3- to 5-day eligibility period * Subjects must complete a minimum of 80% of the daily ePRO diary entry during the baseline period * Female subjects of childbearing potential and male subjects must agree to use contraception for the duration of the study. * Subjects must be willing and able to comply with the study requirements and give informed consent for participation in the study Exclusion Criteria: * Female subjects who are pregnant or breastfeeding * Subjects with systolic blood pressure \<85 mmHg * Subjects with an estimated glomerular filtration rate \<15 mL/min/1.73 m2 * Subjects with an alanine aminotransferase and/or aspartate aminotransferase value \>3 × the upper limit of normal at screening * Subjects who have a digital ulcer infection within 30 days of screening * Subjects with a history of cervica…